Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03285893 · ClinicalTrials.gov registry record
Oral Cell DNA Adducts in Smokers
A clinical trial, sponsored by University of Minnesota.
- Completed
- Registry status
- 281
- Enrollment target
NCT03285893: Completed study, sponsored by University of Minnesota.
NCT03285893 is a clinical trial that has completed, run by University of Minnesota. The registered enrollment target is 281 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03285893 has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- 281 participants
- Enrollment target
Study Summary
DNA adducts in the oral mucosa cells of 100 smokers from 3 ethnic groups - Native Hawaiians, Whites, and Japanese Americans with differing risks for lung cancer upon cigarette smoking will be quantified. DNA adducts of tobacco smoke carcinogens will be quantified using both targeted and untargeted approaches.
Primary Outcome
Acrolein-DNA adduct (8R/S)-3-(2'-deoxyribos-1'-yl)-5,6,7,8-tetrahy- dro-8-hydroxypyrimido\[1,2-a\]purine-10(3H)-one. Model adjusted for age, sex and race/ethnicity
Interventions
- OTHER oral cell DNA adducts
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 281 participants |
| Start Date | 2018-02-01 |
| Est. Completion | 2021-08-01 |
What the finished NCT03285893 record still lists
NCT03285893 is an observational study that tracks outcomes without assigning an intervention. The registered 281 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which oral cell DNA adducts is the first listed.
NCT03285893 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03285893 about?
NCT03285893 is a clinical study titled "Oral Cell DNA Adducts in Smokers". DNA adducts in the oral mucosa cells of 100 smokers from 3 ethnic groups - Native Hawaiians, Whites, and Japanese Americans with differing risks for lung cancer upon cigarette smoking will be quantified. DNA adducts of tobacco smoke carcinogens will be quantified using both targeted and untargeted a...
What is the current status of trial NCT03285893?
This trial is currently completed. The enrollment target is 281 participants. The study started on 2018-02-01. Estimated completion is 2021-08-01.
What interventions are being tested in trial NCT03285893?
The interventions under investigation include: oral cell DNA adducts (OTHER).
Who is sponsoring clinical trial NCT03285893?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04521231 · 281 participants · Phase 1
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
- NCT06190730 · 281 participants · NA
REmote Symptom COllection to improVE postopeRative Care
- NCT02860364 · 282 participants · NA
Comparing Hypothermic Temperatures During Hemiarch Surgery
- NCT04867395 · 282 participants · NA
A Multi-Phase Study Examining Hospital to Home Transitions for Children With Medical Complexity
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI